Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders

• US 20090269356A1
• Filed: 03/08/2007
• Published: 10/29/2009
• Est. Priority Date: 03/08/2006
• Status: Abandoned Application

• Current Assignee: Archemix LLC
• Original Assignee: Archemix LLC
• Inventors: Epstein, David, Kurz, Jeffrey C.
• Application Number:
  US12/224,708
• Publication Number:
  US 20090269356A1
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C12N 15/115 Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
• CPC Class Codes: C12N 2310/16 Aptamers
• CPC Class Codes: C12N 2320/32 Special delivery means, e.g. tissue-specific

Abstract

Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject'"'"'s complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer.

Claims

1. ) A method of treating, stabilizing and/or preventing a complement-mediated ocular disorder, the method comprising the step of administering a therapeutically effective amount of an anti-complement aptamer to a subject in need thereof.

2. ) The method of claim 1, wherein the ocular disorder to be treated is an ocular neovascularization disorder, macular degeneration, diabetic retinopathy, Age Related Macular Degeneration (AMD), inflammatory conjunctivitis, including allergic and giant papillary conjunctivitis, macular edema, uveitis, endophthalmitis, scleritis, corneal ulcers, dry eye syndrome, glaucoma, ischemic retinal disease, corneal transplant rejection, complications related to intraocular surgery such intraocular lens implantation and inflammation associated with cataract surgery, Behcet'"'"'s disease, Stargardt disease, immune complex vasculitis, Fuch'"'"'s disease, Vogt-Koyanagi-Harada disease, subretinal fibrosis, keratitis, vitreo-retinal inflammation, ocular parasitic infestation/migration, retinitis pigmentosa, cytomeglavirus retinitis or choroidal inflammation.

14. ) The method of claim 1, wherein said complement-mediated ocular disorder is a complement-mediated ocular neovascularization disorder and wherein said anti-complement aptamer is administered to a subject in need thereof in an amount sufficient to reduce a symptom of the complement-mediated ocular neovascularization disorder.

15. ) The method of claim 14, wherein the ocular neovascularization disorder to be treated is macular degeneration, AMD, exudative type AMD, or diabetic retinopathy.

31. ) The method of claim 1, wherein the anti-complement aptamer is an aptamer that inhibits a complement target selected from the group consisting of:

a component of an enzymatic complement pathway, a component of a non-enzymatic complement pathway, a component of the membrane attack pathway, a component of the classical complement pathway, a component of the alternative complement pathway, and a component of the lectin pathway.

34. ) The method of claim 1, wherein the anti-complement aptamer is an aptamer that binds to and inhibits a complement component target selected from the group consisting of:

C1, C1q, C1r, C1s, C2, C3, C3a, C3a receptor, C4, C5, C5a, C5a receptor, C5b, C6, C7, C8, C9, Factor B, Factor D, properdin, Mannan Binding Lectin (MBL), MBL Associated Serine Protease 1 and MBL Associated Serine Protease 2.

35. ) The method of claim 1, wherein the complement component target is a human target protein.

36. ) The method of claim 1, wherein the anti-complement aptamer is an aptamer that inhibits C5.

37. ) The method of claim 36, wherein the C5 binding aptamer is selected from the group consisting of:

SEQ ID NOS 1 to 69, 75, 76, 81, 91, 95 and 96.

39. ) The method of claim 1, wherein the anti-complement aptamer is an aptamer that binds to and inhibits C3, C1q, Factor B or Factor D.

42. ) The method of claim 1, wherein the anti-complement aptamer is delivered by ocular administration.

43. ) The method of claim 1, wherein the anti-complement aptamer is delivered by intravitreal administration or peri-ocular administration.

45. ) The method of claim 1, wherein the anti-complement aptamer to be administered is comprised in a depot formulation.

46. ) The method of claim 1, wherein the subject is human.

3_-6. )-6) (canceled)

7. ) A method of stabilizing a complement-mediated ocular neovascularization disorder comprising administering an anti-complement aptamer to a subject in need thereof in an amount sufficient to stabilize the complement-mediated ocular neovascularization disorder.

8. ) The method of claim 7, wherein the ocular neovascularization disorder to be stabilized is macular degeneration, diabetic retinopathy, AMD, or exudative type AMD.

12. ) The method of claim 7, wherein the anti-complement aptamer is administered in an amount sufficient to maintain at least the same level of visual acuity of the subject as compared to the subject'"'"'s visual acuity level upon administration of the anti-complement aptamer.

13. ) The method of claim 7, wherein the anti-complement aptamer is administered in an amount sufficient to maintain about the same level of retinal vessel density of the subject as that of the subject upon administration of the anti-complement aptamer.

9_-11. )-11) (canceled)

16_-20. )-20) (canceled)

21. ) A method of preventing a clinical complement-mediated ocular neovascularization disorder in a subject comprising administering an anti-complement aptamer to a subject in need thereof, in an amount sufficient to prevent a clinical symptom of the complement-mediated ocular neovascularization disorder.

22. ) The method of claim 21, wherein the ocular neovascularization disorder symptom to be prevented is a macular degeneration symptom, an age related macular degeneration symptom, an exudative type age related macular degeneration symptom, or a diabetic retinopathy symptom.

26. ) The method of claim 21, further comprising the step of identifying whether the subject is at risk for clinical complement-mediated ocular neovascularization disorder.

27. ) The method of claim 26, wherein the identifying step comprises detecting the presence of drusen in the subject and detecting no clinical loss of visual acuity.

28. ) The method of claim 26, further comprising the step of identifying the at risk subject by detecting a variation in the subject'"'"'s complement factor H relative to wild type complement factor H.

29. ) The method of claim 21, wherein the anti-complement aptamer is administered in an amount sufficient to prevent the loss of visual acuity in a subject relative to the subject'"'"'s level of visual acuity upon anti-complement aptamer administration.

30. ) The method of claim of 21, wherein the anti-complement aptamer is administered in an amount sufficient to prevent a substantial increase in the level of retinal vessel density in the subject relative to the subject'"'"'s retinal vessel density level upon anti-complement administration.

23_-25. )-25) (canceled)

32_-33. )-33) (canceled)

38. ) The method of claim 32, wherein the C5 binding aptamer is ARC186, ARC187, ARC1905.

40_-41. )-41) (canceled)

44. ) (canceled)

47. ) A method of treating a C5, C5a and/or C5b-9 mediated ocular disorder, the method comprising the step of administering an anti-C5 agent to a subject in need thereof in an amount sufficient to treat the ocular disorder.

48. ) The method of claim 47, wherein the ocular disorder to be treated is an ocular neovascularization disorder.

49. ) The method of claim 47, wherein the ocular disorder to be treated is macular degeneration or diabetic retinopathy or exudative type AMD.

57. ) The method of claim 47, wherein said C5, C5a and/or C5b-9 mediated ocular disorder is treating a C5, C5a and/or C5b-9 mediated ocular neovascularization disorder, and wherein said comprising administering an anti-C5 agent is administered to a subject in need thereof in an amount sufficient to reduce a symptom of the C5, C5a and/or C5b-9 mediated ocular neovascularization disorder.

58. ) The method of claim 57, wherein the ocular neovascularization disorder to be treated is macular degeneration, exudative type AMD, or diabetic retinopathy.

72. ) The method of claim 47, additionally comprising the step of administering to the subject an anti-VEGF agent.

73. ) The method of claim 72, wherein the anti-VEGF agent is selected from the group consisting of:

a nucleic acid molecule, an aptamer, an antisense molecule, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody or antibody fragment, a sugar, a polymer, and a small molecule.

74. ) The method of claim 47, additionally comprising the step of administering to the subject an anti-PDGF agent.

75. ) The method of claim 74, wherein the anti-PDGF agent is selected from the group consisting of:

a nucleic acid molecule, an aptamer, an antisense molecule, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody or antibody fragment, a sugar, a polymer, and a small molecule.

76. ) The method of claim 47, wherein the anti-C5 agent is selected from the group consisting of:

a nucleic acid molecule, an aptamer, an antisense molecule, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody or antibody fragment, a sugar, a polymer, and a small molecule.

77. ) The method of claim 47, wherein the anti-C5 agent is a C5 specific aptamer.

78. ) The method of claim 77, wherein the C5 specific aptamer is selected from the group consisting of:

SEQ ID NOs 1-67, 75-81 and 88-98.

79. ) The method of claim 78, wherein the C5 specific aptamer is SEQ ID NO:

5 or SEQ ID NO;

67.

80. ) The method of claim 47, wherein the anti-C5 agent to be administered is a prodrug.

81. ) The method of according to claim 72, wherein the anti-VEGF agent is a prodrug.

82. ) The method according to claim 74, wherein the anti-PDGF agent is a prodrug.

83. ) The method according to claim 47, further comprising administering an anti-vascular agent.

84. ) The method of claim 83, wherein the anti-vascular agent is a porphyrin derivative.

85. ) The method of claim 84, wherein the method further comprises the step of activating the porphyrin derivative with laser light.

86. ) The method of claim 47, wherein the anti-C5 agent is delivered by ocular administration.

87. ) The method of claim 47, wherein the anti-C5 agent is delivered by intravitreal administration.

88. ) The method of claim 47, wherein the subject is human.

50. ) (canceled)

51. ) A method of stabilizing a C5, C5a and/or C5b-9 mediated ocular neovascularization disorder comprising administering an anti-C5 agent to a subject in need thereof in an amount sufficient to stabilize the C5, C5a and/or C5b-9 mediated ocular neovascularization disorder.

52. ) The method of claim 51, wherein the ocular neovascularization disorder to be stabilized is macular degeneration, exudative type AMD, diabetic retinopathy.

55. ) The method of claim 51, wherein the anti-C5 agent is administered in an amount sufficient to maintain at least the same level of visual acuity of the subject as compared to the subject'"'"'s visual acuity level upon administration of the anti-C5 agent.

56. ) The method of claim 51, wherein the anti-C5 agent is administered in an amount sufficient to maintain about the same level of retinal vessel density of the subject as that of the subject upon administration.

53_-54. )-54) (canceled)

59_-62. )-62) (canceled)

63. ) A method of preventing a clinical C5, C5a and/or C5b-9 mediated ocular neovascularization disorder in a subject comprising administering an anti-C5 agent to a subject, the method comprising the step of administering the anti-C5 agent to the subject in an amount sufficient to prevent a clinical symptom of the C5, C5a and/or C5b-9 mediated ocular neovascularization disorder.

64. ) The method of claim 63, wherein the ocular neovascularization disorder symptom to be prevented is a macular degeneration symptom an exudative type AMD symptom, or a diabetic retinopathy symptom.

67. ) The method of claim 63, wherein the subject is at risk of developing the ocular neovascularization disorder.

68. ) The method of claim 67, further comprising the step of identifying the at risk subject by detecting the presence of drusen in the subject and detecting no clinical loss of visual acuity.

69. ) The method of claim 67, further comprising the step of identifying the at risk subject by detecting a variation in the subject'"'"'s complement factor H.

70. ) The method of claim 63, wherein the anti-C5 agent is administered in an amount sufficient to prevent the loss of visual acuity in a subject relative to the subject'"'"'s level of visual acuity upon anti-C5 agent administration.

71. ) The method of claim of 63, wherein the anti-C5 agent is administered in an amount sufficient to prevent a substantial increase in the level of retinal vessel density in the subject relative to the subject'"'"'s retinal vessel density level upon anti-C5 agent administration.

65_-66. )-66) (canceled)